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Between 1979 and 1984 thirty-seven patients were treated with combination chemotherapy for metastatic
seminoma; 27 of these had relapsed following initial radiotherapy for stage I and IIA disease and 10 patients
with stage IIB-IV disease received chemotherapy de novo followed by radiotherapy to sites of bulk disease.
Treatment consisted of either a cis-platinum containing combination (25 patients), or cyclophosphamide and
etoposide (12 patients). The overall survival of all patients at 5 years was 49%, 34 patients were assessable for
response; a CR was obtained in 8 (24%) and a GPR in 19 (56%), the 5 year survival of this group being 66%
at 5 years. No difference in survival was seen in relation to age, previous irradiation, serum HCG or LDH;
bulk disease however, was an adverse prognostic factor. Survival was similar for both chemotherapy schedules
but neutropenia and life-threatening sepsis was less with the cyclophosphamide etoposide combination.
Seminomas account for approximately 40% of all testicular
tumours (Mostofi, 1973) and the majority (70%) present
without evidence of metastatic disease or minimal infra-
diaphragmatic lymph node involvement. Conventional
treatment with orchidectomy and abdominal irradiation in
this group has resulted in excellent results approximately
95% of patients being alive and disease free five years after
completion of treatment (Read et al., 1983; Peckham, 1981).
For patients with more advanced abdominal disease the
results of radiotherapy alone are less encouraging; a five year
survival rate of 40% being a common finding (Ball et al.,
1982; Thomas et al., 1982).
Reports that metastatic seminoma will respond to
platinum containing combinations (Einhorn & Williams,
1980; Simon et al., 1983) have led to a reappraisal of the
place of chemotherapy similar to that adopted for non-
seminomatous germ cell tumours (NSGCT).
We report here the results of such treatment in patients
with advanced disease and in those patients who relapsed
following conventional X-ray therapy as initial management
for stage I and Ila disease.
Patients and methods
Between 1978 and 1984 37 patients (median age 40, range
21-64) with histologically proven seminoma received
treatment. Twenty-seven had relapsed following initial
radiotherapy and the remaining 10 received chemotherapy
initially followed by X-ray treatment to sites of previous
bulk disease. A testicular primary was identified in 26; the
remaining 11 presented with a retroperitoneal mass.
Assessment
Patients were assessed and staged prior to treatment by
clinical examination, haematological and biochemical profile,
serum AFP and HCG, LDH, chest X-ray and computerised
tomography where appropriate. A creatinine clearance was
determined in patients before, and repeated at appropriate
intervals during treatment.
Sixteen patients had elevated serum /3HCG (>5 U1-1),
and 22 patients had elevated serum lactic dehydrogenase
(LDH) levels (>500U1). None had a raised serum AFP.
Staging
Two comparative staging systems were used: that adopted by
this Institute contrasted with that proposed by the MRC
Working Party for Testicular Tumours, (1985) (Table I).
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Table I Results of staging before chemotherapy described by the
Christie Hospital Staging system and the MRC testicular tumour
working party staging system
Number of
Christie Hospital staging patients
I Disease confined to the testis 0
IIA No clinically residual disease but abdominal 0
nodal involvement established by
investigative procedure
IIB Palpable abdominal disease or scrotal residue 8
III Disease involves mediastinal and/or 13
supraclavicular nodes
IVA Lung metastases, less than 6, not more than 3
2cm diameter
IVB Lung metastases more extensive than IVA 2
IVC Extranodal metastases other than lung (liver 5; 11
bone 3; brain 1; spinal extradural deposits 2)
Number of
MRC tumour volume patients
Small volume 7
Large volume 17
Very large volume 13
Treatment
The chemotherapy used initially for patients presenting in
1978-1980 was a modification of PVB (cis-platin, vinblastine
and bleomycin) as reported by Einhorn & Donohue (1977).
This was later modified to cis-platin, etoposide and
vinblastine (PEV) a regimen found to be as effective for
patients with metastatic teratomas (Wilkinson, 1985). A
combination of cyclophosphamide and etoposide was also
used (12 patients) because of the concern that in some
patients who previously had had radiotherapy a platinum
containing combination might result in impaired renal
function (Read, 1982) (details are given in Table II). It was
also considered for those patients who presented with renal
failure.
The treatment policy was to administer between 4 and 6
courses of chemotherapy; for those patients presenting de
novo with abdominal disease only, chemotherapy was
discontinued once it was felt that the disease could be
encompassed in a satisfactory radiotherapy field as
determined by appropriate CT scanning. Patients generally
received a central mid plane dose of 3,000cGy in 20
fractions over 28 days. All patients with stage IV disease
received 6 courses and a decision concerning radiotherapy
was then made upon the bulk residue as determined by CT
scanning. Those patients who relapsed following
radiotherapy received 6 courses of therapy.
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Table II Details of the PEV, cyclophosphamide-etoposide, and
PVB combinations used in this series
Treatment schedules
(1) PEV
Vinblastine 10mg i.v. day 1 and 2
Etoposide 100mgm-2 day 1-3
Cis-platinum 25mgm-2 day 1-5 with hydration
every 21 days for 4-6 courses
(2) Cyclophosphamide-etoposide
Cyclophosphamide 1.5gm 2 day 1 with hydration
Etoposide 150mgm-2 day 1 and 2
every 21 days for 4-6 courses
(3) PVB (modified)
Vinblastine 10mg i.v. day 1 and 2
Bleomycin 15mg i.m. bd days 1-3
Cis-platinum 20mgm-2 day 1-5 with hydration
every 21 days for 4-6 courses
Response
Response was defined as follows:
1. Complete remission (CR) - no evidence of disease as
determined by clinical, radiological and a marker
estimation.
2. Good partial remission (GPR) - >50% reduction of
initial disease.
3. Poor response (PR) - <50% reduction of initial
disease.
Toxicity was assessed by routine haematological and
biochemistry profiles repeated before and during treatment.
Patients were seen routinely on a weekly basis in the
outpatient clinic in order to detect impending sepsis, etc.
Those patients with a WBC < 1.5 x 1091-1 were routinely
given prophylactic antibiotics.
Survival
Survival curves were calculated by the life table method
(KAPLAN-MEIER) and a log rank test (Peto et al., 1977)
was used to compare survival curves with different groups.
All survivals were calculated from the time ofchemotherapy.
Results
Of the 37 patients who were admitted for therapy, 32
completed chemotherapy (see toxicity section). Twelve
patients proceeded to subsequent radiotherapy; 10 who
received chemotherapy initially and 2 for mediastinal relapse
after conventional irradiation for stage I disease.
Thirty-four patients are evaluable for response. Three
patients were not assessable; one died very early on in
treatment from advanced disease and 2 died shortly after the
first course of treatment from toxicity. (The latter two
patients are included in the toxicity section but are not
assessable for response). The overall response to chemo-
therapy is given in Table III. A complete remission of
disease (CR) was noted in 8/34 patients (24%) and a good
partial response (GPR) in 19/34 (56%). A poor response was
seen in 7 patients (20%).
A common finding following completion of chemotherapy
was a residual mass visible on computerised tomography at
the site of initial bulk disease. Laparotomy in 3 patients
showed fibrosis but no active tumour. It is well recognised
that in patients with particularly bulky abdominal disease,
persisting abdominal masses can be identified after
completion of treatment (Peckham et al., 1985). The overall
survival for the 34 patients from the time of chemotherapy
was 54% at 5 years. Patients with a CR or GPR had a 66%
survival at 5 years, significantly better than those with a
Table III Overall response to chemotherapy; patients treated with
chemotherapy after recurrence following radiotherapy, and treated
with chemotherapy initially
Recurrent
afterprevious
Allpatients radiotherapy Chemotherapy
Response (%) (%) (%)
Complete response 8 (24) 7 (28) 1 (11) Partial response
greater than 50% 19 (56) 12 (48) 7 (78)
Poor response
less than 50% 7 (20) 6 (24) 1 (11)
Total assessable 34 (100) 25 (100) 9 (100) Not assessable 3 2 1
37 27 10
poor response or inevaluable disease (30% at 5 years,
P=0.001) (Figure 1). The overall survival of all 37 patients
is 49% at 5 years.
Prognosticfactors
No difference in survival was seen in relation to age at
treatment, previous irradiation, elevation of serum HCG or
LDH. In particular, the survival at 5 years for the previously irradiated patients was 51%, compared to 50% for the
patients treated with chemotherapy de novo.
The survival was similar in those patients (n=25) treated
with either the cis-platinum containing combinations (PVB
or PEV) (47% at 5 years) and the cyclophosphamide-
etoposide treated group (68%) (n = 12).
The overall survival of all 37 patients by stage at
chemotherapy is shown in Figure 2. The survival at 5 years
was 50% for stage II, 69% for stage III, and 33% for stage IV (see Figure 2). Using the MRC working party criteria
according to bulk disease the survival at 5 years was 71%
for small volume disease, 44% for large volume disease and
38% for very large volume disease.
Those patients who received planned radiotherapy after
chemotherapy had an 83% 5 years survival (12 patients)
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Figure 1 Survival of patients with a complete response or good partial response >50% reduction of initial tumour size n=27
(upper curve), and those with poor response <50% reduction of
initial tumour size or not assessable, n= 10 (lower curve), P=0.001.102 P.M. WILKINSON et al.
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Figure 2 Patient survival by stage at chemotherapy (all patients).
compared to a 38% 5 years survival of those who did not
(P=0.17). However, longer follow-up is required to
determine if this difference is clinically relevant.
Relapse
Sixteen patients have relapsed (Table IV). Of the 5 patients
with liver metastases initially, three remain alive and in
complete remission. Of the three patients with CNS disease,
one with a spinal epidural deposit is alive and well; all 3
patients with bone metastases have died.
Toxicity
Treatment toxicity was examined in all 156 treatment cycles
in the 37 patients. All regimens used caused vomiting and
alopecia. Two patients with advanced tumours died early in
treatment and although postmortem examination was
inconclusive, we regarded these as treatment deaths. Two
patients discontinued chemotherapy after three cycles
because of pancytopenia; both these obtained a remission
with subsequent radiotherapy. One patient died during
treatment with advanced tumour.
The major toxic effects of chemotherapy are seen in
Table V, comparing the toxicity of cis-platinum containing
combinations (PVB and PEV) and the combination of
cyclophosphamide and etoposide. Where applicable toxicity
is described by WHO grading (1979).
Table IV Vital status of all 37 patients, those treated
with chemotherapy after recurrence following
radiotherapy and those treated with chemotherapy
initially
Recurrent
after previous
radiotherapy Chemotherapy
Alive and well 14 5
Alive with disease 1 0
Toxic death I I
Tumour death 11 4
27 10
Table V Chemotherapy toxicity comparing toxicity in cis-platinum
combinations PVB and PEV (113 treatment cycles) and the
cyclophosphamide-etoposide combination (43 patient cycles) WHO
grading is shown where applicable.
Cyclo-
Cis-platinum phosphamide-
regimens etoposide
No. of No. of
episodes episodes
Toxicity (%) (%)
Neutropenia ( x 1091-1)
Grade 1 & 2 (> 1.0 & <2.0) 16 (14) 3 (7)
Grade 3 (>0.5& <1.0) 38(34) 6(13)
Grade 4 (<0.5) 33 (29) 10 (23)
Sepsis
Grade 1 (minor) 4 (4) 0
Grade 2 (moderate) 5 (4) 6 (13)
Grade 3 (major) I (1) 0
Grade 4 (major/hypotension) 2 (2) 0
Renal function creatinine (mmol1 1)
>0.1 & <0.2 25 (22) 10 (23)
>0.2 1 (1) 0
Peripheral neuropathy
Grade 1 (mild) 13 (12) 0
The incidence of neutropenia and serious sepsis was less
with the cyclophosphamide-etoposide combination. The two
toxic deaths occurred with cis-platinum containing
combinations. The cyclophosphamide-etoposide combination
was subjectively much better tolerated.
No difference in toxicity was noted in previously
irradiated patients; however this may reflect the planned
dose reductions necessary for these patients.
Discussion
In view of the high relapse of patients with advanced
seminoma treated by radiotherapy alone there is a trend now
to use chemotherapy initially for the management of such
patients. There is no doubt that seminoma is a chemo-
sensitive disease but the optimum management at the present
is not as easy to define as it is for NSGCT.
There are a number of factors responsible for this. The
assessment of response to treatment is difficult because of
the common finding of residual masses after completion of
treatment (only 24% of patients in this series had a complete
radiological evidence of tumour regression). Similarly, these
masses regress slowly after completion of therapy and unless
patients are subjected to resective surgery then it is not
possible to determine whether viable elements are present.
Surgical excision of residual disease following chemo-
therapy for patients with seminoma is not universally
practised. Indeed, the dense fibrotic reaction makes a
complete retroperitoneal lymph node dissection difficult if
not impossible in this situation. It is interesting to note that
in a recent series of patients who underwent surgery for
residual masses 5/20 patients were found to have viable
seminoma (Montzer et al., 1986). This strengthens the
argument for giving post-operative radiotherapy to patients
in this situation.
The absence of a reliable marker for metastatic seminomas
also makes the assessment of progress difficult. The majority
of seminomas do not secrete beta HCG, and placental
alkaline phosphatase has not proven to be satisfactory
(Lange et al., 1982). Patients with advanced seminoma are
generally much older than those patients with NSGCT, and
there can be differences in drug tolerance. Patients may have
had previous abdominal radiotherapy which compromisesTREATMENT OF ADVANCED SEMINOMA 103
bone marrow and renal function and enlarged abdominal
node masses may cause obstructive uropathy.
In the choice of the optimum initial drug regimen
platinum containing combinations may not be the most
appropriate. The encouraging response noted in this series
with the cyclophosphamide/etoposide combination was
somewhat surprising. There are no substantial series that
have accrued sufficient patient numbers to assess the merit
of cyclophosphamide alone in metastatic seminoma.
However, in view of the fact that no significant differences
were noted between this and the alternative platinum
containing regimen it can be considered as an alternative
form of therapy. This is particularly important in terms of
toxicity and it must be stressed that toxicity with this
regimen was less than that of the platinum containing
combination for those patients with compromised renal
function, for those who relapsed after radiotherapy and in
the more elderly patient where there was considered to be a
problem with tolerance of cis-platinum.
In comparative terms the results of therapy in this series
are similar to those of other groups that have adopted a
similar treatment policy. There will inevitably be variation in
response rates in results from different centres depending
upon entry criteria and the results in a selected series is
shown in Table VI and contrasted with those obtained here.
Thus, Peckham et al (1985) using a combination pre-
dominantly of PEB but also PVB obtained an overall
response rate of 31/33 patients (94%) with a median follow-
Table VI Comparison of results of treatment of advanced
seminoma (selected series).
Number Currently Median
of CR/GPR NED FU
Author Therapy patients (%) (%) (months)
Oliver PVB 12 10 (85) NS 30
(1984) cis-P 14 10 (71)
Peckham et al. PVB 8 7 (88) 31 (94) 36
(1985) PEB 25 24 (96)
Schuette et al. PVB 28 25 (90) 23 (82) 28
(1985) +A
Loehrer et al. PVB 60 41 (68) 37 (62) NS
(1987) +A
Wilkinson PVB 34 27 (80) 19 (56) 50
(1987) PEV
C/E
P=cis-platinum; V =Vinblastine; E =Etoposide; A =Adriamycin;
B =Bleomycin; C =Cyclophosphamide.
up of 36 months; although only a small proportion of
patients had bulk disease. Oliver (1984) using PVB obtained
a response of 10/12 patients (83%) and with cis-platin as a
single agent 10/14 patients (71%); the results in this series
were less favourable if the patients had had prior irradiation.
Schuette et al. (1985) using a combination PVB+adriamycin
observed a response of 25/28 (89%) and 23 (82%) of these
patients are subsequently disease free with a median follow-
up of 28 months. Loehrer et al. (1987) in a recent series of
60 patients treated with PVB+adriamycin obtained a
complete response in 41 patients (60%) and 37 of these are
currently disease free. The response of patients treated here
with chemotherapy initially are very similar to those of other
groups and this series contains a high population of patients
with bulk disease. In a recent summation of results 157/201
patients achieved a GPR/CR (81%) (Loehrer et al., (1987)
and thus, initially the results of treatment are similar to that
for NSGCT. However, there is a tendency for late relapses in
seminoma and it is only with the passage of time that we
will get a true indication of overall remission rates.
Following chemotherapy, radiotherapy was given to sites
of initial bulk disease if patients had not previously been
irradiated. Other groups have failed to show an advantage
by such a policy (Peckham et al., 1985 & Schuette et al.,
1985) and this series suggests an improved survival for those
patients who received such management. However, this may
be because the group is pre-selected and longer follow-up is
necessary to assess whether radiotherapy offers an
advantage. It should also be considered though, in salvaging
patients where chemotherapy proves to be unacceptable or
where relapse occurs at a localised site following treatment.
We have only limited experience with the new platinum
analogue carboplatin and therefore we cannot usefully
comment on the merits of the drug in this situation. There
are, however, encouraging reports that this drug either alone
or in combination can be effective (Peckham et al., 1985) but
it is likely to be some time before a satisfactory regimen can
be standardised that will be suitable for all patients. Also,
long term follow-up is required to gain an accurate figure of
efficiency of treatment. The median follow-up in this series is
50 months and we would expect other series to show a
similar trend in survival when the appropriate trials have
matured.
In conclusion this series confirms the usefulness of
aggressive combination chemotherapy in advanced semi-
noma, although the optimum regimen and the place of
radiotherapy remains to be fully resolved. However, because
of its toxicity it is unlikely to replace radiotherapy in the
management ofearly stage disease after orchidectomy.
Because of the small number of patients accrued in any
one specialised centre there are advantages to cooperative
studies to try and resolve some of the problems posed by
this study.
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